Pharsight

Fanapt generic

Fanapt is an antipsychotic drug owned by Vanda Pharms Inc. It contains the active ingredient iloperidone and was first authorized for market use on 06 May, 2009. Fanapt is available in tablet form for oral administration.

When will Fanapt generic be available?

The generics of Fanapt are expected to be released after 28 December, 2031. This is due to the expiration of the last patent on that day, paving the way for a possible generic version. So far, all 9 drug patents held by Vanda Pharms Inc. for Fanapt are still active.

Fanapt uses

Fanapt is predominantly used in the treatment of schizophrenia. It works by modifying the dosage to reduce the risk associated with QT prolongation not induced by other drugs during treatment with iloperidone. The dosage is also adjusted in patients who are poor metabolizers of CYP2D6, and in those who are being treated with Fluoxetine.

Fanapt patent expiration

Fanapt holds 9 active drug patents, with the last one set to expire on 28 December, 2031. This patent expiration date serves as a potential timeline for the release of the Fanapt generic. Below are the details of the patent:

Litigations filed on Fanapt

Fanapt dosage

Want to ask something?